Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Vaccine Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
The Biopharma sector witnesses a pivotal publication revealing extensive insights into vaccine collaboration and licensing deals. This contemporary analysis delivers an unparalleled understanding of the partnerships cementing the future of vaccine research and distribution. The report meticulously details the nature and framework of agreements which have shaped the vaccine landscape from 2016 to 2023.
Research and Development Drive Vaccine Alliances
The in-depth report unfolds the intricacies of vaccine deals, emphasizing the multifaceted components involving collaborative R&D and the commercialization of the resulting products. It showcases the strategic framework companies utilize to streamline research initiatives and maximize the dissemination of vaccines globally.
Unveiling Financial Structures and Strategic Alliances
Within its pages lies a comprehensive listing of over 700 vaccine deals including financial details where available. This listing is complemented with an accessible format, providing direct links to the online records of actual partnering agreements and, where available, the SEC-filed contract documents.
Deal Analysis and Trends
The report commences with an informative chapter offering a sweeping overview of deal trends since 2016. It continues by highlighting the leading vaccine deals in terms of value and the most active companies in vaccine dealmaking. The compilation provides vital information for stakeholders to gauge the market value and identify key players in the vaccine deal landscape.
- A detailed orientation of vaccine dealmaking trends
- Top 25 companies' activity profiles
- A directory of deals organized by various categories
Key Findings and Report Utilization
Designed for a broad spectrum of readers, from industry executives to researchers, the report is instrumental in understanding the current vaccine deal trends. Analyzing the detail of these agreements aids stakeholders in:
- Assessing the nature of rights granted within these partnerships
- Understanding the payment frameworks and scalability of deals
- Scrutinizing sales audit mechanisms and agreement terms
Essential Aid for Due Diligence and Competitive Benchmarking
The report deeply explores the structure of deals, offering a critical tool for due diligence and competitive benchmarking. It addresses a variety of considerations including exclusivity, payment structure, intellectual property management, commercialization responsibilities, and legal jurisdiction. This compilation stands as a crucial resource for anyone seeking to keep abreast of the dynamic field of vaccine development and the strategic partnerships that bring novel immunizations to the forefront of public health solutions.
For More Information
To delve into the details presented in the Vaccine Collaboration and Licensing Deals report, each record offers an online access point to associated contract documents, providing comprehensive insights at the click of a button. This rich repository of data reflects the evolving dynamics of the Biopharma industry's commitment to addressing global health challenges through collaborative innovation in vaccine development.
Key Topics Covered
- Introduction
- Trends in Vaccine Dealmaking
- Overview of Vaccine Deals
- Most Active Deal Makers
- Deal Types and Therapy Areas
- Industry Sector Analysis
- Deal Terms Analysis
- Leading Vaccine Deals
- Top Deals by Value
- Most Active Vaccine Dealmakers
- Overview of Active Deal Makers
- Profiles of Top Deal Making Companies
- Vaccine Contracts Dealmaking Directory
- Overview of Vaccine Contracts
- Directory of Vaccine Deals
- Vaccine Dealmaking by Technology Type
- Analysis of Dealmaking Trends
- Deal Directory
- Vaccine Deals by Company
- Vaccine Deals by Type
- Vaccine Deals by Therapy Area
Companies Mentioned
- 2A
- 3D Medicines
- 3SBio
- 4D Pharma
- A*STAR’ Institute of Molecular and Cell Biology
- ABEC
- ABIVAX
- AGC Biologics
- Agenus Bio
- Agilvax
- AIM ImmunoTech
- Akers Biosciences
- Amyris
- Analytical Bio-Chemistry Laboratories
- AnGes MG
- Anixa Biosciences
- Battelle
- Batu Biologics
- CCT Research
- Celldex Therapeutics
- Cellular Biomedicine
- Celonic
- Diavax Biosciences
- Diaxonhit
- DNA Script
- DNAtrix
- Dr. Reddy's Laboratories
- Frederick National Laboratory For Cancer Research
- Fred Hutchinson Cancer Research Center
- Fujifilm
- GISCAD Foundation
- GlaxoSmithKline
- Hefei Sageland Biotechnology
- Helmholtz Zentrum Munchen
- MinervaX
- Recipharm
- Sanofi
- Wyss Institute
- Xenetic Biosciences
- XstalBio
- Y-Biologics
- Y-mAbs Therapeutics
- Yale University
- Yamaguchi University
- Yisheng Biopharma
- Zenoaq
- Zoetis
- Zolovax
- Zuellig Pharma China
- Zydus Cadila
- ZYUS Life Sciences
For more information about this report visit https://www.researchandmarkets.com/r/dcr22k
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
